Amalgamated Financial’s Cytek Biosciences CTKB Stock Holding History

Amalgamated Financial’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$164K	Buy	+15,225	New	+$206K	﹤0.01%	1973

Other funds holding CTKB

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MGM

Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Amalgamated Financial's CTKB Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Cytek Biosciences (CTKB) in Q1 2022: 15,225 shares worth $164K. The stake represents ﹤0.01% of the portfolio and ranks #1973 among its holdings.

74 funds tracked by Wall St. Rank hold CTKB as of Q1 2022.

Amalgamated Financial held 15,225 shares of Cytek Biosciences worth $164K as of Q1 2022.
Cytek Biosciences was a new Amalgamated Financial position in Q1 2022.
Cytek Biosciences made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1973 holding.
74 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.